Name: KalVista Pharmaceuticals, Inc. (KALV) Financial Statements
Creator: FinSpry

KalVista Pharmaceuticals Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scale:

Scroll to see more

KalVista Pharmaceuticals, Inc. income statement - Annual data in millions USD
Breakdown	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Dec 2025	Apr 2024	Apr 2023	Apr 2022	Apr 2021	Apr 2020	Apr 2019
Revenue & Gross Profit
Revenue	0.00	0.00	0.00	0.00	0.00	12.69	16.13
Cost of Revenue	0.00	86.17	80.28	70.17	41.29	0.00	0.00
Gross Profit	0.00	-86.17	-80.28	-70.17	-41.29	12.69	0.00
Operating Expenses
Research & Development	71.71	86.17	80.28	70.17	41.29	40.19	35.02
Selling, General & Administrative	116.29	54.28	30.60	26.45	16.64	13.03	10.93
Operating Expenses	188.00	54.28	110.87	81.31	57.92	53.22	45.95
Operating Income	-188.00	-140.45	-110.87	-81.31	-57.92	-40.53	-29.82
Other Income/Expense
Interest Income	6.44	3.90	2.23	1.09	0.90	0.00	1.40
Interest Expense	5.79	0.00	0.00	0.00	0.00	0.00	0.00
Other Income/Expense	7.94	8.44	-15.64	-2.12	-9.93	-9.83	7.73
Income
Income Before Tax	-180.05	-126.64	-92.91	-82.34	-46.24	-29.24	-20.69
Income Tax Expense	3.39	0.00	0.00	0.00	0.00	-0.12	0.12
Net Income	-183.44	-126.64	-92.91	-82.34	-46.24	-29.12	-20.82
Net Income - Continuous Operations	-183.44	-126.64	-92.91	-82.34	0.00	0.00	0.00
Net Income - Discontinued Operations	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBITDA	-173.33	-139.63	-91.22	-80.75	-45.06	-28.54	-29.44
EBIT	-188.00	-140.45	-92.91	-81.31	-46.24	-29.24	-29.82
Depreciation & Amortization	0.94	0.82	0.70	0.56	0.50	0.51	0.00
Earnings Per Share
Basic EPS	-4.00	-3.00	-3.00	-3.00	-2.00	-2.00	-1.00
Diluted EPS	-4.00	-3.00	-3.00	-3.00	-2.00	-2.00	-1.00
Basic Shares Outstanding	49.65	36.79	27.89	24.47	19.09	17.75	15.08
Diluted Shares Outstanding	49.65	36.79	27.89	24.47	19.09	17.75	15.08